Not Accepting Cases

Crestor Lawsuits

Hundreds of people who said they were injured by the popular cholesterol drug Crestor sued maker AstraZeneca. Those lawsuits have all been dismissed, withdrawn or quietly settled. A whistleblower lawsuit filed by former AstraZeneca employees was still pending in Texas in March 2018.

Crestor 10mg Pills
Crestor Lawsuit Facts
  1. Injuries Diabetes, rhabdomyolysis (severe muscle damage), liver damage, kidney damage, sudden death
  2. Defendants AstraZeneca Inc. (manufacturer), McKesson Corporation (distributor)
  3. Top Settlement Undisclosed

Editors carefully fact-check all Drugwatch content for accuracy and quality.

Drugwatch has a stringent fact-checking process. It starts with our strict sourcing guidelines.

We only gather information from credible sources. This includes peer-reviewed medical journals, reputable media outlets, government reports, court records and interviews with qualified experts.

Related Pages

* UPDATE: Courts dismissed most Crestor lawsuits. The rest were settled or withdrawn. Drugwatch’s legal partners are not accepting Crestor cases at this time.

Crestor’s side effects have been blamed in lawsuits. These side effects include kidney damage, liver damage, severe muscle injury and Type 2 diabetes.

Crestor users filed more than 1,200 lawsuits in California state courts. Judges dismissed more than 1,000 of those lawsuits filed by out-of-state plaintiffs.

AstraZeneca released a financial report on Feb. 2, 2018. The report said the company resolved all product liability claims involving Crestor. The company didn’t disclose any further information.

Four former AstraZeneca employees filed whistleblower lawsuits in 2013 against the company. The Texas attorney general joined the consolidated case. As of March 2018, that lawsuit was still pending in Travis County, Texas.

Drugwatch’s legal partners are not accepting cases involving Crestor. But this could change in the future.

Status of Crestor Lawsuits

Hundreds of patients filed lawsuits blaming Crestor for injuries. California courts dismissed the vast majority of those lawsuits.

According to AstraZeneca, it has resolved all product liability lawsuits involving Crestor.

Injuries Mentioned in Crestor Lawsuits

Patients who sued AstraZeneca blame Crestor for various serious conditions. These injuries include diabetes and rhabdomyolysis.

Rhabdomyolysis is a severe muscle injury that can damage the kidneys.

Lawsuits also mentioned liver damage.

Patients blamed Crestor for severe muscle injuries, diabetes and liver damage.

Accusations Against AstraZeneca

People who filed lawsuits said AstraZeneca knew Crestor was defective and dangerous. They said AstraZeneca failed to warn the public about the risks of taking Crestor.

Lawsuits also accuse the company of deceptively and misleadingly promoting the drug. And they allege AstraZeneca failed to adequately test Crestor.

Crestor pills 10 mg
An example of Rovustatin 10 mg pills, which were marketed by AstraZeneca as Crestor.

Crestor Class Action

There is no known class-action lawsuit filed over Crestor in the U.S.

According to AstraZeneca financial filings, plaintiffs in a lawsuit in Tel Aviv, Israel, filed motions in 2012 and 2013 to certify that case as a class action. Then the plaintiffs withdrew from the action in 2016, and the case concluded.

Crestor Verdicts and Settlements

It does not appear that any lawsuits filed by patients injured by Crestor resulted in a jury trial. So, there haven’t been any verdicts.

A small number of lawsuits may have settled, but the terms have not been disclosed. There have not been any large, publicized settlements.

FDA: Crestor Ads Were Misleading

In 2004, consumer advocacy group Public Citizen petitioned the U.S. Food and Drug Administration to recall Crestor over safety concerns. That December, AstraZeneca took out full-page newspaper ads defending the drug.

The FDA said the ads minimized the risks of Crestor and contained false or misleading claims that the drug was superior to other options.

The ads targeting consumers compared Crestor to competing statins. The comparison was based on results from a 2003 STELLAR study that compared four statins. The statins were Crestor, Lipitor, Pravachol and Zocor.

The FDA said the comparison wasn’t accurate and the ads were misleading. For instance, the largest doses of Crestor and Lipitor are 40 mg and 80 mg. But the ads compared 40 mg of Crestor to 80 mg of Lipitor.

The FDA asked AstraZeneca to stop running the ads. At the same time, the agency rejected the Public Citizen petition to recall Crestor.

Did You Know?
The FDA asked AstraZeneca to stop misleading ads about Crestor.

Researchers Tie Crestor Sales to Free Meals

A 2016 study in JAMA Internal Medicine looked at how pharmaceutical companies marketed different drugs to persuade doctors to write more prescriptions for their products. Crestor was one of the four drugs researchers followed.

Researchers looked at 279,669 doctors who received a total of 63,524 payments from drug companies. Doctors who received a free meal were more likely to prescribe the drug being pitched than a competing medicine. As the number of meals or their value increased, so did the doctors’ relative prescribing rates.

Whistleblower Lawsuits

Four former AstraZeneca employees sued AstraZeneca as whistleblowers in Texas and Delaware. The U.S. government declined to join the cases. But the Texas Attorney General’s Office joined the Texas case.

The lawsuits accuse AstraZeneca of promoting Crestor for uses that were not approved by the FDA. They accuse the company of defrauding Medicaid by certifying that the drug was not in violation of the law.

AstraZeneca moved the case filed in Travis County to federal court. A federal judge later granted a motion from the attorney general to return the case to county court. It remained pending in country court as of March 2018.

The Delaware federal case was on hold pending the outcome of the Texas case. A spokeswoman for the Texas Attorney General’s Office told Drugwatch on March 2, 2018, that there hasn’t been much movement on the case.

Please seek the advice of a medical professional before making health care decisions.

Related Pages

Did you find Drugwatch helpful?

8 Cited Research Articles

  1. AstraZeneca. (2017). 2016 Annual Report. Retrieved
  2. AstraZeneca. (2018, February 2). Full-Year 2017 Results. Retrieved
  3. Herrera et al vs. Astrazena Pharmaceuticals et al. (2013, March 4). Superior Court of the State of California in and for the County of Los Angeles. Complaint for Damages and Demand for Jury Trial. Retrieved
  4. State v. AstraZeneca. (n.d.). Online docket. Case Number D-1-GV-13-000812. Retrieved from
  5. Public Citizen. (2004, October 29). Letter Renewing Call for Rosuvastatin (Crestor). Retrieved
  6. DeJong, C. et al. (2016, August). Pharmaceutical Industry-Sponsored Meals and Physician Prescribing Patterns for Medicare Beneficiaries. Retrieved
  7. Steinbrook, R. (2016, August). Industry Payments to Physicians and Prescribing of Brand-Name Drugs. Retrieved
  8. Harris, G. (2004, December 22). FDA Calls Ads for Cholesterol Pill Crestor “False and Misleading.” Retrieved
View All Sources
Who Am I Calling?

Calling this number connects you with Wilson and Peterson, LLP or one of its trusted legal partners. A law firm representative will review your case for free.

Wilson and Peterson, LLP funds Drugwatch because it supports the organization’s mission to keep people safe from dangerous drugs and medical devices.

(888) 645-1617

To contact Drugwatch Managing Editor Kevin Connolly, call (855) 839-9780.